| |
Managing High Risk Cardiovascular Patients: Understanding the Neuronal Hormonal Mechanisms and End-Organ Protection
Eight AAFP Prescribed Credits Approved Up to 4.0 AMA PRA Category 1 Credits™
Date:
Saturday, April 24, 2010
Location:
The InterContinental Kansas City at the Plaza 401 Ward Parkway Kansas City, MO 64112
Get Driving Directions
Statement of Purpose:
One of every 3 Americans – and half of those 60 and above - has hypertension, the most common risk factor for cardiovascular disease. Although effective treatment options are available, 65 percent of Americans with hypertension are untreated or undertreated. Nearly one third of adults with high blood pressure are unaware of their condition, increasing the risk of associated complications and diseases.
Effective risk management has been associated with a 35 to 40 percent reduction in the incidence of strokes, a 20 to 25 percent reduction in the incidence of heart attacks and a 50 percent reduction in the incidence of heart failure.
The renin-angiotensin system plays a key role in the regulation of blood pressure, and blockade of this system now forms a central part of strategies to reduce the risk for cardiovascular events in high-risk patients. Both angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) have been shown to be effective in lowering blood pressure and reducing the risk for cardiovascular events.
This CME activity will focus on the role of the renin-angiotensin system, and the importance of effective drug therapy to affect this mechanism, preventing cardiovascular risk and preventing end-organ damage.
Learning Objectives:
The CME learning objectives and topics have been selected to provide the most pertinent information to family physicians, general practitioners, general internists, emergency medicine, obstetricians/gynecologists, nurse practitioners and physician assistants. Upon completion of this program, registrants should be able to:
1. Recognize that uncontrolled hypertension presents a remarkable risk for cardiovascular disease, particularly in patients with other risk factors. 2. Apply JNC-7 goals and treatment recommendations for hypertensive patients at high risk for cardiovascular disease. 3. Differentiate the modes of action of cardiovascular risk-reducing drugs and which medications are most effective in specific patients. 4. Evaluate the renin-angiotensin system and its role in blood pressure regulation and cardiovascular risk. 5. Use the understanding of the role of the renin-angiotensin system to prevent cardiovascular disease and end-organ damage in high risk patients. 6. Formulate a treatment plan to improve self-management in adherence to dietary, lifestyle and drug treatment of high risk patients. 7. Employ effective communications tools and techniques to help patient understanding of the importance of maintaining goal cardiovascular risk markers in high risk patients.
Accreditation:
ACCME: Antidote Education Company is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Antidote designates this educational activity for a maximum of 4.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. AAFP: This activity has been reviewed and is acceptable for up to 8 Prescribed credits by the American Academy of Family Physicians. Four of these credits conform to the AAFP criteria for evidence-based CME clinical content. CME credit has been increased to reflect 2 for 1 credit for only the EB CME portion. When reporting CME credit, AAFP members should report total Prescribed and Elective credit earned for this activity. It is not necessary for members to label credit as evidence-based CME for reporting purposes. AOA: This program has been accredited by the American Osteopathic Association for 4 credit hours of AOA Category 2-A credit. AANP: “This program is approved for 4.0 contact hours of continuing education (which includes 2.27 hours of pharmacology) by the American Academy of Nurse Practitioners. Program ID 1003074.” AAPA: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.
Faculty:
Michael Fleming, MD, FAAFP - Assistant
Clinical Professor of Family Medicine and Comprehensive Care at LSU Health
Science Center School of Medicine in Shreveport, and Assistant Clinical
Professor of Family Medicine in the Department of Family and Community Medicine
at Tulane University Medical School. Senior Medical Director, Antidote
Education Company.
Jean-Bernard Durand, MD, FACP, FCCP, FACC - Associate Professor of Medicine; Director, Cardiovascular Genetics Research; Medical Director, Cardiomyopathy Services, University of Texas MD Anderson Cancer Center, Houston, TX
John B. Crider, MD - Adjunct Clinical Faculty, University of Alabama School of Medicine, Birmingham, AL; Family Medical Clinic, LLC, Medical Staff, Marshall Medical Center North, Arab, AL
Sue Stableford, MPH, MSB - Director, Health Literacy Institute, University of New England, Portland, ME
Schedule:
Saturday, April 24, 2010
| 7:30 a.m. - 8:00 a.m.
| Registration and Buffet Breakfast
| 8:00 a.m. - 8:15 a.m.
| Welcome note from Antidote staff
| 8:15 a.m. - 9:00 a.m.
| John B. Crider Interactive presentation: Improving Cardiovascular Risk: Effective Therapy
| 9:00 a.m. - 10:00 a.m.
| Jean-Bernard Durand Interactive presentation: The Neuronal Hormonal Basis of Cardiovascular Risks
| 10:00 a.m. - 10:15 a.m.
| Break
| 10:15 a.m. - 11:15 a.m.
| John B. Crider, Jean-Bernard Durand Interactive workshop: Matching patient to therapy – case studies in cardiovascular risk management
| 11:15 a.m. - 12:00 p.m.
| Sue Stableford Interactive video case based presentation: Helping the Patient Help Themselves
| 12:00 p.m. - 12:30 p.m.
| John B. Crider, Jean-Bernard Durand, Sue Stableford Clinical Discussion Panel: Putting the Pieces Together
|
Case Presentations:
One of the most important learning tools in
continuing medical education is the interactive discussion among practicing
physicians and our expert speaker panel. Antidote Education Company encourages
our registrants to actively participate in this exercise. We invite you
to send synopses of your most unusual or difficult diagnostic or treatment
challenges to us to be included in these discussions. Send these to our
medical director, Dr. Michael Fleming, at:
Antidote Education Company
14850 Quorum Drive, Suite 325
Dallas, Texas 75254
Fax: 214-346-9322
Program Evaluation:
Each registrant will be asked to complete an
evaluation form on each speaker and topic. The results of these
evaluations are utilized in speaker recruitment and in the planning of future
seminars.
Certificate of Attendance
Upon completion of the seminar, a certificate of
attendance will be provided to each participant.
Educational Grant
This CME activity is supported by an unrestricted
educational grant from
Novartis.
General Information:
Antidote Education Company does not provide overnight
accommodations or rates. Overnight accommodations are the responsibility
of the CME activity participant. Please contact the
The InterContinental Kansas City at the Plaza
directly at
816-756-1500 - main line
or on their website at www.kansascityic.com to book overnight rooms.
Special Notes:
The faculty request that registrants submit cases of the high-risk cardiovascular patients you have encountered recently in practice. They will review the cases and choose several to address in the Clinical Discussion Panel.
If you have a challenging or unique patient case you would like the faculty to consider, please click here to send in your submission.
This accredited continuing medical
education program is copyright © 2008 by Antidote Education Company.
|
|
|